Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
暂无分享,去创建一个
R. Larson | F. Appelbaum | S. Devlin | M. Tallman | R. Stone | M. Othus | S. Geyer | D. Zannino | J. Rowe | D. Goldman | S. Coutre | D. Douer | H. Erba | M. Litzow | B. Powell | M. Collins | E. Stein | P. Wiernik | Ju-Whei Lee | Jae H. Park | H. Iland | S. Mantha | K. Laumann
[1] L. Campbell,et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. , 2015, The Lancet. Haematology.
[2] J. Bergeron,et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan‐Canadian epidemiological study , 2014, British journal of haematology.
[3] M. Tallman,et al. Acute promyelocytic leukemia: what is the new standard of care? , 2014, Blood reviews.
[4] H. Dombret,et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients , 2014, Leukemia.
[5] R. Larson,et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy , 2014, British journal of haematology.
[6] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[7] J. Reynolds,et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). , 2012, Blood.
[8] L. Shih,et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia , 2012, European journal of haematology.
[9] J. Reynolds,et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia , 2012, Haematologica.
[10] J. Reynolds,et al. All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 ) , 2012 .
[11] M. Schymura,et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. , 2011, Blood.
[12] M. Baccarani,et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. , 2011, Blood.
[13] M. Höglund,et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry , 2011, Leukemia.
[14] Yunsuk Choi,et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. , 2011, Leukemia research.
[15] R. Larson,et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.
[16] M. Sanz,et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. , 2010, Blood.
[17] H. Dombret,et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.
[18] W. Hiddemann,et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG , 2009, Leukemia.
[19] J. Esteve,et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.
[20] T. Naoe,et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome , 2007, European journal of haematology.
[21] J. Rowe,et al. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. , 2005, Thrombosis research.
[22] C. Bloomfield,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .
[23] L. Pagano,et al. Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Gruppo Italiano Malattie Ematologiche dell'Adulto. , 2002, Blood.
[24] C. Bloomfield,et al. All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .
[25] F. Mandelli,et al. Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia , 2000, British journal of haematology.
[26] J. Miguel,et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.
[27] O. Yamada,et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] T. Barbui,et al. Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .
[29] T. Barbui,et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.
[30] F. Mandelli,et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.
[31] E. Freireich,et al. Treatment of adult acute myeloblastic leukemia. , 1979, Haematology and blood transfusion.
[32] A. Naidoo,et al. Treatment of acute leukemia in children. , 1976, Canadian Medical Association journal.
[33] G. Humphrey,et al. Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000‐2500 rads tumor dose) in treatment for meningeal leukemia , 1975, Cancer.
[34] E. Frei,et al. Comparative effects of the antitumor agents 5-(Dimethyltriazeno)-imidazole-4-carboxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L1210 leukemia cells in vivo. , 1970, Cancer research.